QL535 / Qilu Pharma - LARVOL DELTA

QL535, A novel CD2-costimulating T cell engager targeting PSMA-positive prostate cancer matching CD28 trispecific antibody in cytotoxicity, minimizing cytokine release and T-cell exhaustion (AACR 2025) - "In conclusion, QL535 is a novel trispecific T cell engager with improved anti-tumor efficacy and safety profile. These findings warrant further clinical investigation to evaluate its safety and efficacy in patients."

Trispecific • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD2 • CD58 • CD8 • CXCL8 • FOLH1 • IFNG • IL6 • TNFA